SCHEMBL5773950

SCHEMBL5773950

Cc1nccn1N([C]=O)c1ccccn1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
LIPE Q05469 1/20 0.34
ALDH1A1 P00352 4/20 0.34
KDM4E B2RXH2 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
PPARG P37231 2/20 0.32
HDAC1 Q13547 1/20 0.32
PPARA Q07869 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
POLB P06746 1/20 0.31
CYP2E1 P05181 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2A6 P11509 1/20 0.31
MAPT P10636 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL316609 0.68 CYP2D6 (0.48) CYP2D6CYP2C19ALDH1A1KDM4ESMN1; SMN2
SCHEMBL5113337 0.67 CYP2D6 (0.42) CYP2D6CYP2C19ALDH1A1KDM4ESMN1; SMN2
SCHEMBL8715074 0.67 PLD1 (0.45) CYP2D6CYP2C19ALDH1A1KDM4ESMN1; SMN2
SCHEMBL1448809 0.65 CYP2D6 (0.41) CYP2D6CYP2C19ALDH1A1KDM4ESMN1; SMN2
SCHEMBL4086997 0.64 SLC6A2 (0.42) KDM4ECYP2E1CYP3A4CYP2A6MAPT
SCHEMBL1186136 0.64 CYP2D6 (0.41) CYP2D6CYP2C19ALDH1A1KDM4ESMN1; SMN2
SCHEMBL6638291 0.64 ALDH1A1 (0.41) CYP2D6CYP2C19ALDH1A1KDM4ESMN1; SMN2
SCHEMBL1185718 0.64 CYP2D6 (0.44) CYP2D6CYP2C19ALDH1A1KDM4ESMN1; SMN2
SCHEMBL9183264 0.63 ALDH1A1 (0.44) CYP2D6CYP2C19ALDH1A1KDM4ESMN1; SMN2
SCHEMBL21883942 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060084690-A1 Isoxazole derivatives MOMOSE YU 2006-04-20 US disclosed
US-7022725-B2 Isoxazole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-04 US disclosed
US-20040048908-A1 Isoxazole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-11 US disclosed
EP-1340749-A1 ISOXAZOLE DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084690-A1 Isoxazole derivatives INSR, GPR119, INSRR CYP2D6 192/4885CYP2C19 28/4885LIPE 297/4885
US-20040048908-A1 Isoxazole derivatives GPR119, INSR, IRS1 CYP2D6 190/4885CYP2C19 34/4885LIPE 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.